Traditional randomized trials are often impractical for treatments in the rare and ultra rare disease space.
Dr. Patricia E. Greenstein
Advertisement
Articles by Dr. Patricia E. Greenstein
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
3
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
4
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
5